€5.60
(5.91%)
Add to watchlist
Create an alert
Stocks and Shares ISAAbivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Information
About this company
Key people
Sylvie L. Gregoire
Chairwoman of the Board
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Keith Fournier
Senior Vice President - Global Regulatory Affair
Marc de Garidel
Chief Executive Officer
Dominik Hoechli
Director
Corinna Zur Bonsen-Thomas
Independent Director
Troy A. Ignelzi
Independent Director
June H. Lee
Independent Director
Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Ida Hatoum
Chief People Officer, Chief Compliance Officer
Jerome Denis
Vice President - Process Development and Manufacturing
Hema Keshava
Senior Vice President - Finance
Patrick Malloy
Head of Investor Relations
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Maurus de la Rosa
Senior Vice President - Research
Click to see more
Key facts
- Shares in issue63.47m
- EPICABVX
- ISINFR0012333284
- LocationFrance
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap€7.51bn
- Employees69
- ExchangeEuronext Paris
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.